相关实验视频

Updated: May 10, 2025

Genetic Variant Detection in the CALR gene using High Resolution Melting Analysis

Genetic Variant Detection in the CALR gene using High Resolution Melting Analysis

Published on: August 26, 2020

在分子瘤板癌样本中,HRR基因改变和HRD之间的有限关联:谁应该测试HRD?

Christoph Schubart^1,2,3,4,5, Lars Tögel^1,2,3,4,5, Maria Giulia Carta^1,2,3,4,5

¹Institute of Pathology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.

International journal of cancer

|April 25, 2025

概括

同源复合修复 (HRR) 基因突变并不总是与同源复合缺陷 (HRD) 相关. 除了基因分析之外,还建议进行泛癌HRD测试,以指导PARP抑制剂治疗决策.

科学领域:

在瘤学瘤学.
遗传学遗传学是一个
基因组学就是基因组学.

背景情况:

同源复合修复 (HRR) 途径基因变异与同源复合缺陷 (HRD) 相相关.
HRD是Poly (ADP-ribose) 聚合酶抑制剂 (PARPi) 治疗的已知生物标志物.
分子瘤板 (MTBs) 在晚期癌症患者中识别可采取行动的分子变化.

研究的目的:

调查HRR基因突变在泛癌MTB队列中的HRR基因突变与HRD的流行率和相关性.
评估基因组不稳定性得分 (GIS) 的实用性,作为各种瘤类型中HRD的衡量标准.
为了评估HRR基因突变状态之外的HRD测试的临床相关性,用于PARPi治疗选择.

主要方法:

对237名患有多种瘤实体的MTB患者的回顾性分析.
评估HRR基因突变状态 (BRCA1/2和其他).
基因组不稳定性评分 (GIS ≥42) 的评估作为HRD的替代品.

主要成果:

在38.1%具有BRCA1/2突变的样本中观察到高GIS (≥42),10.9%具有其他HRR基因变异,4.3%没有HRR基因突变.
不同的非活化BRCA1/2突变并不总是与高GIS相关.
由高GIS表示的HRD存在于具有野生型HRR基因的瘤子集中.

结论:

全癌症HRD评估,包括GIS,建议与HRR基因突变分析一起用于PARPi治疗指南.
HRR可以作为PARPi治疗的独立生物标志物,即使没有HRR基因突变.
需要进一步的研究来确定非卵巢癌类型的GIS值.

关键词:

人力资源副主任HRD 运输系统运营商500-HRD 分子瘤板是一个分子瘤板.泛癌癌症癌症癌症

更多相关视频

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

Published on: July 22, 2020

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

相关概念视频

Hazard Ratio

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...

Homologous Recombination

Homologous Recombination

The basic reaction of homologous recombination (HR) involves two chromatids that contain DNA sequences sharing a significant stretch of identity. One of these sequences uses a strand from another as a template to synthesize DNA in an enzyme-catalyzed reaction. The final product is a novel amalgamation of the two substrates. To ensure an accurate recombination of sequences, HR is restricted to the S and G2 phases of the cell cycle. At these stages, the DNA has been replicated already and the...

The Ras Gene

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...